Millendo Therapeutics, Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.9902
- Today's High:
- $2.1900
- Open Price:
- $1.9999
- 52W Low:
- $1.26
- 52W High:
- $9.88
- Prev. Close:
- $1.9500
- Volume:
- 19867
Company Statistics
- Market Cap.:
- $0.030 billion
- Book Value:
- 2.33
- Revenue TTM:
- $0.000 billion
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0.000 billion
- Gross Profit TTM:
- $0.000 billion
- Profit Margin:
- 0%
- Return on Assets TTM:
- -47.15%
- Return on Equity TTM:
- -94.03%
Company Profile
Millendo Therapeutics, Inc had its IPO on 2012-11-12 under the ticker symbol MLND.
The company operates in the sector and industry. Millendo Therapeutics, Inc has a staff strength of 37 employees.
Stock update
Shares of Millendo Therapeutics, Inc opened at $2 at the start of the last trading session i.e. 2022-11-02.
The stocks traded within a range of $1.99 - $2.19, and closed at $2.12.
This is a +8.72% increase from the previous day's closing price.
A total volume of 19,867 shares were traded at the close of the day’s session.
In the last one week, shares of Millendo Therapeutics, Inc have increased by +6%.
Millendo Therapeutics, Inc's Key Ratios
Millendo Therapeutics, Inc has a market cap of $0.030 billion, indicating a price to book ratio of 0.6995 and a price to sales ratio of 0.
In the last 12-months Millendo Therapeutics, Inc’s revenue was $0.000 billion with a gross profit of $0.000 billion and an EBITDA of $-0.034 billion. The EBITDA ratio measures Millendo Therapeutics, Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Millendo Therapeutics, Inc’s operating margin was 0% while its return on assets stood at -47.15% with a return of equity of -94.03%.
In Q2, Millendo Therapeutics, Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Millendo Therapeutics, Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- None
Its diluted EPS in the last 12-months stands at $-2.869 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of None. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Millendo Therapeutics, Inc’s profitability.
Millendo Therapeutics, Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.3426. Its price to sales ratio in the trailing 12-months stood at 0.
Millendo Therapeutics, Inc stock pays annual dividends of $None per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $0.000 billion
- Total Liabilities
- $0.000 billion
- Operating Cash Flow
- $0.000 billion
- Capital Expenditure
- $0.000 billion
- Dividend Payout Ratio
- 0%
Millendo Therapeutics, Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.
Millendo Therapeutics, Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.
Millendo Therapeutics, Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.
In 1970, Millendo Therapeutics, Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.
Comparatively, Millendo Therapeutics, Inc paid $0 billion in dividends in 1970.
Other key metrics
- Current Trading Price
- $2.12
- 52-Week High
- $9.88
- 52-Week Low
- $1.26
- Analyst Target Price
- $4.33
Millendo Therapeutics, Inc stock is currently trading at $2.12 per share. It touched a 52-week high of $9.88 and a 52-week low of $9.88. Analysts tracking the stock have a 12-month average target price of $4.33.
Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at 1.52 indicating a short percent outstanding of 3%.
Around 1130% of the company’s stock are held by insiders while 6547.2% are held by institutions.
Frequently Asked Questions About Millendo Therapeutics, Inc
Similar Industry Stocks ()
Most Active
Top Gainers
Top Losers
About
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company’s lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; and nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia. Millendo Therapeutics, Inc. is headquartered in Ann Arbor, Michigan.